Case Report
Year 2022,
Volume: 4 - Supplement 1, 117 - 119, 01.04.2022
Abstract
Epidermal growth factor receptor (EGFR) monoclonal antibody inhibitors are used to treat metastatic colorectal cancers. Cetuximab, an EGFR inhibitor drug, targets specific molecular pathways and does not cause the severe systemic side effects seen in cytotoxic chemotherapy. Herein, we presented a case who developed acneiform eruptions during cetuximab treatment.
References
- Broadbridge VT, Karapetis CS, Price TJ. Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25.
- Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, Braun M, Fenwick J, Saunders MP. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol. 2018 Oct;14(24):2531-41. doi: 10.2217/fon-2018-0187.
- Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1834-6. doi: 10.1056/ NEJMe0806778.
- Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic toxicity occurring during anti- EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: A systematic review. Clin Colorectal Cancer. 2018 Jun;17(2):85-96. doi: 10.1016/j.clcc.2017.12.004.
- Nguyen A, Hoang V, Laquer V, Kelly KM. Angiogenesis in cutaneous disease: part I. J Am Acad Dermatol. 2009 Dec;61(6):921-42; quiz 943-4. doi: 10.1016/j.jaad.2009.05.052.
- Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007 Feb;56(2):317-26. doi: 10.1016/j. jaad.2006.09.005.
- Sipples R. Common side effects of anti-EGFR therapy: Acneform rash. Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):28-34. doi: 10.1016/j.soncn.2006.01.013.
Year 2022,
Volume: 4 - Supplement 1, 117 - 119, 01.04.2022
Abstract
References
- Broadbridge VT, Karapetis CS, Price TJ. Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25.
- Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, Braun M, Fenwick J, Saunders MP. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol. 2018 Oct;14(24):2531-41. doi: 10.2217/fon-2018-0187.
- Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1834-6. doi: 10.1056/ NEJMe0806778.
- Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic toxicity occurring during anti- EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: A systematic review. Clin Colorectal Cancer. 2018 Jun;17(2):85-96. doi: 10.1016/j.clcc.2017.12.004.
- Nguyen A, Hoang V, Laquer V, Kelly KM. Angiogenesis in cutaneous disease: part I. J Am Acad Dermatol. 2009 Dec;61(6):921-42; quiz 943-4. doi: 10.1016/j.jaad.2009.05.052.
- Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007 Feb;56(2):317-26. doi: 10.1016/j. jaad.2006.09.005.
- Sipples R. Common side effects of anti-EGFR therapy: Acneform rash. Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):28-34. doi: 10.1016/j.soncn.2006.01.013.
There are 7 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Case Reports |
| Authors | |
| Publication Date | April 1, 2022 |
| Submission Date | February 10, 2022 |
| Acceptance Date | March 9, 2022 |
| Published in Issue | Year 2022 Volume: 4 - Supplement 1 |
e-ISSN: 2687-4245
Turkish Journal of Internal Medicine, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2023 -TJIM.org